Castle Biosciences (CSTL) - Cash per Share

Castle Biosciences relies on the US domestic market, remaining sensitive to reagent supply disruptions. The cash per share trend, where the current value equals 8.96, links these risks to the expansion strategy for skin genetic tests. Meanwhile, financial stability is based on recognized melanoma diagnostic standards, although profitability is limited by fixed insurance reimbursement rates.
Comprehensive metric breakdowns and analytics for Castle Bio (CSTL)

To identify drivers of resilience, the investor analyzes the ratio of total liquid assets to the number of shares outstanding, as reflected in the change in cash per share. This indicator determines the internal margin of safety for Castle Biosciences (CSTL), allowing the company to mitigate the risks of shortages in imported reagents and chips should geopolitical disruptions occur within global supply chains.